| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/21/2011 | US20110178069 Inhibitors of interleukin-1 beta converting enzyme |
| 07/21/2011 | US20110178016 Pulse parathyroid hormone for treatment of the hematopoietic syndrome, stromal cell loss, and vascular injury resulting from acute exposure to lethal radiation |
| 07/21/2011 | US20110178006 Method for administering glp-1 molecules |
| 07/21/2011 | US20110178000 Apoptotically Active Peptides |
| 07/21/2011 | US20110177595 Multipotent Adult Stem Cells, Sources Thereof, Methods of Obtaining and Maintaining Same, Methods of Differentiation Thereof, Methods of Use Thereof and Cells Derived Thereof |
| 07/21/2011 | US20110177154 Tubular nanostructure targeted to cell membrane |
| 07/21/2011 | US20110177152 Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease |
| 07/21/2011 | US20110177150 Implantable tissue compositions and method |
| 07/21/2011 | US20110177130 Methods for preparation of lipid-encapsulated therapeutic agents |
| 07/21/2011 | US20110177085 Bitter Taste Receptors |
| 07/21/2011 | US20110177073 Recombinant production of mixtures of antibodies |
| 07/21/2011 | US20110177066 Prevention and treatment of amyloidogenic diseases |
| 07/21/2011 | US20110177057 Pharmaceutical preparation and manufacturing method thereof |
| 07/21/2011 | US20110177056 Non-cytotoxic fusion proteins comprising egf muteins |
| 07/21/2011 | US20110177027 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
| 07/21/2011 | US20110177009 Drug carrier providing mri contrast enhancement |
| 07/21/2011 | US20110177004 Version of FDG Detectable by Single-Photon Emission Computed Tomography |
| 07/21/2011 | CA2785970A1 Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability |
| 07/20/2011 | EP2345742A1 RNA sequence-specific mediators of RNA interference |
| 07/20/2011 | EP2345728A1 Yeast membrane protein expression system and its application in drug screening |
| 07/20/2011 | EP2345715A2 Schwann cells originating in myeloid interstitial cells |
| 07/20/2011 | EP2345660A1 Anti-xdr-tb agent, anti-mdr-tb agent, and combined anti-tuberculous agent |
| 07/20/2011 | EP2345649A1 Benzimidazole compound in crystal form and salt thereof |
| 07/20/2011 | EP2345644A1 Indazole compound |
| 07/20/2011 | EP2345637A2 3, 10, and 12a substituted tetracycline compounds |
| 07/20/2011 | EP2345636A1 Casr agonist |
| 07/20/2011 | EP2345425A2 Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs |
| 07/20/2011 | EP2345424A1 CD4-specific antibody TRX1 and uses therefor |
| 07/20/2011 | EP2345415A1 Therapeutic/prophylactic agent for prostate cancer |
| 07/20/2011 | EP2345409A1 Therapeutic agent for adult t-cell leukemia |
| 07/20/2011 | EP2344528A1 Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof |
| 07/20/2011 | EP2344471A1 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| 07/20/2011 | EP2344145A1 Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods |
| 07/20/2011 | EP2168581A9 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 07/20/2011 | EP1997511B1 Therapeutic agent for rheumatoid arthritis |
| 07/20/2011 | EP1778724B9 Antiangiogenic peptides |
| 07/20/2011 | EP1458748B1 Apoptotically active peptides |
| 07/20/2011 | EP1181317B1 An integrin heterodimer and an alpha subunit thereof |
| 07/20/2011 | CN1993469B Recombinant alpha-fetoprotein, method and means for preparation thereof, compositions on the base thereof and use thereof |
| 07/20/2011 | CN102131926A Transfection agent |
| 07/20/2011 | CN102131785A 6-substituted isoquinolines and isoquinolinones |
| 07/20/2011 | CN102131774A Novel pyrrole derivative having, as substituents, ureide group, aminocarbonyl group and bicyclic group which may have substituent |
| 07/20/2011 | CN102131547A Sparc anti-inflammatory activity and uses thereof |
| 07/20/2011 | CN102131525A Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 07/20/2011 | CN102127057A Dipeptidyl peptidase inhibitors |
| 07/20/2011 | CN102127054A 3-(substituted dihydroisoindol-2-yl)-2,6-piperidinedione polymorph and pharmaceutical composite |
| 07/20/2011 | CN102127053A Dipeptidyl peptidase inhibitors |
| 07/20/2011 | CN102125690A Application of polyphenol components in preparation of medicaments for treating aspirin resistance |
| 07/20/2011 | CN102125610A Xiaojin sustained-release pellets and composition thereof |
| 07/20/2011 | CN102125557A Use of flibanserin in the treatment of sexual disorders |
| 07/20/2011 | CN101519372B Benzo [e] isoindazole-1,3 diketone compound used as GSK inhibiting agent and preparation method thereof |
| 07/20/2011 | CN101484190B Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| 07/20/2011 | CN101454286B Method for producing phenoxypyridine derivative |
| 07/20/2011 | CN101333156B Preparation method and uses of antrodia camphorate pimelie kelone compounds |
| 07/20/2011 | CN101305007B Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as PDE5 inhibitors |
| 07/20/2011 | CN101300000B Equol level regulator |
| 07/20/2011 | CN101230375B Jellyfish originated glycoprotein having fatigue resistant activity and preparation technique thereof |
| 07/20/2011 | CN101177427B Compound polycrystalline type alpha and solvate for hypnotism, preparation method and combination including the same |
| 07/20/2011 | CN101112236B Health products having a hypoxia-tolerance function |
| 07/20/2011 | CN101076519B Amide compound and thrombopoietin receptor activator |
| 07/19/2011 | US7982067 Phenethanolamine derivatives for treatment of respiratory diseases |
| 07/19/2011 | US7982041 Camptothecin analogs and methods of preparation thereof |
| 07/19/2011 | US7982037 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 |
| 07/19/2011 | US7981899 Skin aging resistance, wrinkling resistance; (S)-1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid |
| 07/19/2011 | US7981895 Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group |
| 07/19/2011 | US7981861 Method of performing angioplasty with a GLP-1 molecule |
| 07/19/2011 | US7981676 Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins |
| 07/19/2011 | US7981631 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment and monitoring of periodontal diseases |
| 07/19/2011 | US7981598 Preventive/remedy for respiratory diseases |
| 07/19/2011 | US7981427 has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43 |
| 07/19/2011 | US7981420 Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) |
| 07/19/2011 | US7981413 Using cell surface adhesion proteins specific immunoglobulin to target therapeutics to tumorous; immunodiagnostics; immunotherapy |
| 07/19/2011 | CA2609733C 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative |
| 07/19/2011 | CA2485677C Methods of treating allergic reactions |
| 07/19/2011 | CA2485503C Phenyl-thiophene type vitamin d receptor modulators |
| 07/19/2011 | CA2476186C Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 07/19/2011 | CA2475818C Aryl ureas as kinase inhibitors |
| 07/19/2011 | CA2465272C Separation of regioisomers of metal phthalocyanines |
| 07/19/2011 | CA2448561C Aminoquinoline derivatives and their use as adenosine a3 ligands |
| 07/19/2011 | CA2441996C Non-nucleoside reverse transcriptase inhibitors |
| 07/19/2011 | CA2432464C Excitatory amino acid receptor antagonists |
| 07/19/2011 | CA2431606C Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| 07/19/2011 | CA2341441C Methods of using and compositions comprising dopamine reuptake inhibitors |
| 07/19/2011 | CA2321900C Agents with serotonin-related activity for the treatment for sleep apnea |
| 07/19/2011 | CA2291740C Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 07/19/2011 | CA2237590C Cyclic and heterocyclic n-substituted .alpha.-iminohydroxamic and -carboxylic acids |
| 07/19/2011 | CA2220555C Methods and compositions for healing and repair of connective tissue attachment |
| 07/19/2011 | CA2185656C Protein tyrosine kinase agonist antibodies |
| 07/14/2011 | WO2011084625A1 Systems and methods for x-ray flourescence computed tomography imaging with nanoparticles |
| 07/14/2011 | WO2011083823A1 Prophylactic or therapeutic agent for schizophrenia |
| 07/14/2011 | WO2011083804A1 Indole derivative |
| 07/14/2011 | WO2011083738A1 Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application |
| 07/14/2011 | WO2011083637A1 Therapeutic agent for hepatic disorder |
| 07/14/2011 | US20110172434 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| 07/14/2011 | US20110172298 Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol |
| 07/14/2011 | US20110172290 Isoforms of eIF-5A: Senescence-induced eIF5A; Wounding-induced elF-5A; Growth elF-5A; and DHS |
| 07/14/2011 | US20110172284 Methods for treating spinal muscular atrophy |
| 07/14/2011 | US20110172277 Pirfenidone therapy and inducers of cytochrome p450 |
| 07/14/2011 | US20110172243 Use of azaperone for reducing antibiotic usage |
| 07/14/2011 | US20110172239 Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease |